Kyverna Therapeutics, Inc.'s total assets for Q3 2024 were $339.20M, a decrease of -6.59% from the previous quarter. KYTX total liabilities were $36.49M for the fiscal quarter, a 23.23% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.